Antibody-guided drug shows encouraging activity in metastatic breast cancer
Saturday, December 12, 2009 - 09:49
in Health & Medicine
SAN ANTONIO, TX -- A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher. Link: http://www.dfci.harvard.edu